Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Semaglutide"


25 mentions found


CNN —Barbra Streisand is addressing a divisive comment she wrote under a photo that actor Melissa McCarthy posted on her Instagram page on Monday. In the comment, Streisand asked McCarthy if she took Ozempic – a popular weight loss medication, among its other functions – spurring backlash online. “Below them was a photo of my friend Melissa McCarthy who I sang with on my Encore album,” she wrote. I forgot the world is reading!”CNN has reached out to representatives for McCarthy and Streisand for comment. Ozempic is a brand name for the generic drug semaglutide, and is approved by the US Food and Drug Administration to treat diabetes.
Persons: Barbra Streisand, Melissa McCarthy, Streisand, McCarthy, Ozempic, she’d, , , Adam Shankman Organizations: CNN, Center, US Food and Drug Administration
As diabetes and weight-loss drugs like Ozempic and Wegovy took off in the last few years, many people turned away from established diet and nutrition products. Now, two retailers that specialize in nutritional supplements — GNC and the Vitamin Shoppe — are trying new approaches to win over people who are taking those drugs or who are interested in them. GNC is dedicating a wall of supplements in its more than 2,300 stores to products that it believes will appeal to people on Ozempic, which contains the compound semaglutide, and other drugs that are known as GLP-1 medicines. The chain is also training workers to help customers assess which substances could help them manage common side effects of those prescription drugs. Michael Costello, chief executive of GNC, said his company saw a “big opening” in helping individuals taking such drugs for weight loss.
Persons: Wegovy, Michael Costello
Last year was called the year of Ozempic, though it was also a year of Ozempic backlash and Ozempic shortages, which could persist for years. Even so, we appear very far from a peak for GLP-1 drugs, like Ozempic and Wegovy, which are powered by a molecule called semaglutide, and Mounjaro, which uses its cousin tirzepatide. It seems possible to imagine a future in which almost everyone is taking some variety of GLP-1 drug, and with a pretty good reason to do so. Patients on Ozempic and Wegovy can lose 15 to 20 percent or more of their weight in a little over a year, and if they stay on the drugs, the weight tends to stay off. Semaglutide has been shown to eliminate or reduce the need for insulin among those with recent-onset Type 1 diabetes.
Persons: tirzepatide, Wegovy, we’ve, Semaglutide Locations: Alzheimer’s
How Ozempic Is Transforming a Small Danish Town
  + stars: | 2024-04-20 | by ( Eshe Nelson | ) www.nytimes.com   time to read: +1 min
As the sun sets over the harbor in Kalundborg, a small town about 60 miles west of Copenhagen, light streams through the glass walls of Shaun Gamble’s cafe and bathes his afternoon customers in a warm glow. Nearby, at a sprawling manufacturing plant, Novo Nordisk makes nearly all of its semaglutide, the active ingredient in the company’s wildly popular diabetes and obesity treatments Ozempic and Wegovy. It’s the largest manufacturing investment in Denmark by a company, and it’s happening in this town of fewer than 17,000 people. Novo Nordisk plans to add 1,250 jobs to the existing 4,500 employees at the Kalundborg plant. A highway is being extended; investors are snapping up houses and planning new construction; universities have begun offering biotech courses to feed Novo Nordisk and nearby businesses with workers.
Persons: Shaun Gamble’s Organizations: Novo Nordisk, Nordisk Locations: Kalundborg, Copenhagen, Denmark, Novo
Eli Lilly said it plans to ask U.S. regulators to expand Zepbound's label to include obstructive sleep apnea, or OSA, later this year. Shares of Eli Lilly have ridden the GLP-1 craze to new heights over the past few years. The current standard of care for obstructive sleep apnea is positive airway pressure, or PAP, machines, which help keep patients' airways open while they sleep. Analysts projected obstructive sleep apnea revenue of $3 billion. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.
Persons: Eli Lilly, Zepbound, it's, Mounjaro, Lilly, Jim Cramer, Jim, Eli Lilly YTD, Morgan Stanley, Jim Cramer's, Eli Lilly’s, Brendan Mcdermid Organizations: Novo Nordisk, GLP, OSA, Mayo, U.S, CNBC, Cleveland Clinic, National Council, Aging, Deutsche Bank, American Diabetes Association, Novo Nordisk's Ozempic, Bank of America Locations: U.S, Novo, New York City
European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator said Friday. The review examined several drugs from Novo Nordisk , including Wegovy and Ozempic. Clinical trials from Novo Nordisk and Eli Lilly have not demonstrated a link between GLP-1s and suicidal thoughts. The probe also included other active ingredients in older weight loss and diabetes drugs, including dulaglutide, exenatide and lixisenatide. Results from another study conducted by the agency also did not support a link between GLP-1 drugs and the risk of suicidal thoughts.
Persons: Eli Lilly, couldn't, Liraglutide Organizations: Novo Nordisk, European Union, European Medicines Agency, U.S . Food, Drug Administration, EMA, Icelandic Medicines Agency Locations: London, Britain, Novo, U.S, GLP, Wegovy, Ozempic
The study, published Saturday in the New England Journal of Medicine, showed how the drug helped people with Type 2 diabetes who also had one of the most common kind of heart failure, obesity-related heart failure with preserved ejection fraction. Obesity-related heart failure with preserved ejection fraction can severely limit a person’s ability to participate in the activities of daily life. Often, people with type 2 diabetes who have this kind of heart failure have a more severe form than those who don’t have diabetes. People with a more severe form of heart failure sometimes don’t respond as well to medication as those with less severe disease. One death in the Wegovy group and four in the placebo group were related to cardiovascular issues.
Persons: Wegovy, Ozempic, Dr, Mikhail Kosiborod, , ” Kosiborod, Naveed Sattar, ” Sattar, Sanjay Gupta, Kosiborod, Organizations: CNN, New England, of Medicine, Novo Nordisk –, US Food and Drug Administration, FDA, St, University of Glasgow, Science Media, CNN Health, American College of Cardiology Locations: Asia, Europe, North, South America, Kansas City , Missouri, Atlanta
Costco is now selling the weight loss drug Ozempic through a partnership with health startup Sesame. Still, that doesn't cover the cost of the GLP-1 drug, which has gained popularity but can be costly. Now, you can get a prescription for the weight loss drug Ozempic through the retailer, too. For $179, members can get a prescription for the GLP-1 weight loss drug plus a meeting with a doctor or specialist. Ozempic, Wegovy, and other GLP-1 drugs have gained popularity among people trying to lose weight over the last few years.
Persons: , Michael DiLorenzo, DiLorenzo, Sesame, weren't, Michael Botta Organizations: Costco, Service, CNN, Business, Sesame, Novo Nordisk Locations: Denmark
The warehouse retailer is now offering its US members access to prescriptions for GLP-1 weight loss drugs through its low-cost health care partner Sesame. Costco first partnered with Sesame, a direct-to-consumer health care marketplace that connects medical providers nationwide with consumers, last fall when it began offering its members online health checkups for as low as $29. “The number one search term of Costco members seeking primary care on Sesame was around weight loss,” Goldhill said in an interview with USA Today. JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population. It also made a $100 million-plus deal to buy Sequence, a telehealth business that can offer virtual prescriptions, where appropriate, to patients for these weight loss drugs.
Persons: Sesame, David Goldhill, ” Goldhill, WeightWatchers Organizations: New, New York CNN, Costco, USA, CNN, JPMorgan Locations: New York
A new GLP-1 drug, pemvidutide, helped patients lose fat while guarding muscle, like exercise does. That's impressive when you compare it to existing GLP-1 drugs like Ozempic and Wegovy (semaglutide), or Mounjaro and Zepbound (tirzepatide). This is why doctors recommend patients on weight loss drugs do some strength training in tandem with their medication. Pemvidutide, like tirzepatide is a two-part drug that combines a GLP-1 drug with another drug in a single shot. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss," Scott Harris, Altimmune's chief medical officer, said in a release.
Persons: Drugmakers Eli Lilly, , Drugmaker Altimmune, Altimmune, Scott Harris, Eli Lilly, FierceBiotech, Versanis Organizations: Novo Nordisk, Service Locations: Altimmune, GLP
Some health experts have said that obesity drugs could shrink critical muscle mass, which could raise the risk of injuries and decrease strength. Those results are similar to those often seen with diet and exercise programs for weight loss. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss." For example, Eli Lilly is testing whether combining its weight loss drug with a monoclonal antibody from Versanis Bio might help patients lose weight while preserving muscle mass. The pharmaceutical giant recently acquired Versanis, which is part of a slate of companies targeting the muscle-loss aspect of weight loss.
Persons: Altimmune, Eli Lilly, Scott Harris Organizations: Novo Nordisk, Novo Nordisk's Ozempic Locations: Altimmune's, Novo
The label expansion may improve insurance coverage for Wegovy, which costs more than $1,300 per month out of pocket before any discounts. Many insurers, including Medicare, don’t cover drugs for weight loss, leaving patients scrambling to afford them. “This patient population has a higher risk of cardiovascular death, heart attack and stroke,” he added. More studies need to be done to show whether there are heart benefits for people who haven’t had a cardiac event. Wegovy continues to be in shortage, along with other GLP-1 medicines, as drugmakers struggle to keep up with demand.
Persons: CNN — Wegovy’s, , Dr, Harlan Krumholz, hasn’t, Eli Lilly, Wegovy, John Sharretts, haven’t, it’s, Sanjay Gupta, Jody Dushay, Beth, Dushay, Novo, Doug Langa, Organizations: CNN, US Food and Drug Administration, Yale University, Yale New Haven Hospital, Novo Nordisk, Diabetes, , CNN Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Novo Nordisk’s, North America Operations
Oprah Winfrey will not seek reelection to the board of WW International, known as WeightWatchers. It was a surprising time to jump on board — WeightWatchers had been shedding users, and its stock price was dwindling. AdvertisementDespite not naming the brand, there was an immediate spike in demand for GLP-1 medications — the popular new class of weight-loss drugs. That same day, WW added a weight-loss drug arm to its business, acquiring Sequence, a service that provides weight-loss drugs. AdvertisementLong-term, WW needs to find a new identityOver time, WW will benefit from being a purveyor of hard-to-access weight-loss drugs.
Persons: Oprah Winfrey, , Oprah giveth, Oprah taketh, maven, Winfrey, — WeightWatchers, Axios, Oprah, Forbes, Craig, Alex Fuhrman, Winfrey's, We're, Atkins Organizations: WW International, Service, SEC, Guardian, People Magazine, MarketWatch, Mayo Clinic, Business, Smithsonian's National Museum of, CNBC, Slate Locations: GLP, WeightWatchers
Biotech company Viking Therapeutics saw stock prices double after a report on weight loss drug VK2735. The new drug could lead to even more weight loss at a faster pace than Ozempic or Mounjaro. Viking Therapeutics, a small California-based biotech company, shared the topline results from a mid-stage trial of its drug VK2735 on February 27. AdvertisementHowever, the early results of clinical trials suggest it could be on par to offer even more weight loss in less time than its competitors. How Viking Therapeutics' weight-loss drug worksVK2735 mimics two hormones that affect weight control.
Persons: , Eli Lilly, GIP, VK2735 Organizations: Biotech, Viking Therapeutics, Service, Novo Nordisk, Washington Post, Therapeutics, Viking Locations: California
Just weeks after its initial public offering, Fractyl Health is catching Wall Street's attention as the next potential biopharmaceutical darling. Analysts are highlighting the company's groundbreaking therapies that directly target the gut and pancreas to ultimately induce Type 2 diabetes maintenance and weight loss. "Growing evidence indicates the gut is a core regulator of metabolism, placing gut dysfunction as a root cause of metabolic disease. Indeed, emerging consensus links modern diets to changes in the gut and pancreas that in turn increase an individual's risk of developing Type 2 Diabetes and obesity," Ulz wrote. gut) root cause of disease, could result in a more durable, disease-modifying treatment, differentiated from current, more burdensome (i.e.
Persons: Morgan Stanley, Jason Gerberry, Michael Ulz's, Ulz, Gerberry, Rejuva, America's Gerberry Organizations: Bank of America, Evercore ISI, Fractyl's, Bank, America's Locations: Fractyl
CNN —There is still much researchers don’t know about popular weight loss medications — and those lack of studies could have consequences for eating disorders, according to experts. As the medication become more available, experts said they worry about the impact of these weight loss products on eating disorders. “The eating disorder field is hard because we’re just ignored.”Can these drugs treat binge eating disorder? Binge eating disorder is the most common eating disorder. “A lot of eating disorders do begin with restricted food intake and weight loss,” she said.
Persons: , Aaron Keshen, Jennifer Gaudiani, Susan McElroy, Linda, Harry Fath, McElroy, , ” McElroy, ” Keshen, it’s, Keshen, Gaudiani, ” Gaudiani, “ it’s, , haven’t Organizations: CNN, Nova, Disorder, National Association, Disorders, Gaudiani Clinic, Lindner, of HOPE, University of Cincinnati College of Medicine, International Locations: Nova Scotia, Dalhousie University’s, Halifax , Nova Scotia, United States, Denver, Minnesota
Read previewKelly Osbourne shared in a recently published interview that she's fully in support of using Ozempic, days after her mother, Sharon Osbourne, made headlines criticizing the drug for its effects. "I think it's amazing," Osbourne told E! Stars like Amy Schumer and Chelsea Handler have been outspoken about their negative experiences using Ozempic. Sharon previously cautioned against using Ozempic and said losing weight can become addicting. News, Kelly explained why she thinks the weight-loss drug is spoken about in a negative light.
Persons: , Kelly Osbourne, she's, Sharon Osbourne, Osbourne, who's, Jae C, Amy Schumer, Chelsea Handler, Sharon, Kelly Organizations: Service, CBS, Business, Guardian, BI
How to access the new weight loss drugs
  + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com   time to read: +7 min
(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.
Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, , ” Eli Lilly, Tirrell, , Sima Sistani Organizations: CNN, , Trilliant Health, Novo Nordisk, US Food and Drug Administration, , Nordisk,
Read previewSharon Osbourne has expressed regret over taking the buzzy weight-loss drug Ozempic, stating that she now weighs less than 100 pounds and "can't put on weight." In an interview with The Guardian, Osbourne, 71, highlighted the downsides of Ozempic, a diabetes drug that also causes weight loss. She said that after dropping 42 pounds in four months, she's now "through with the weight loss and all that cosmetic stuff." Osbourne has previously talked about her experience taking the weight loss drug. Sharon Osbourne said her husband Ozzy Osbourne claims she looks like Nancy Reagan following her weight loss.
Persons: , Sharon Osbourne, Osbourne, she's, Ozzy Osbourne, Nancy Reagan, Gregg DeGuire, I've, it's, Ozempic, Elon Musk, Charles Barkley, Amy Schumer Organizations: Service, Guardian, Business, Daily Mail, The Recording, Ozempic, FDA, The Times
The $7 billion healthcare startup Ro, which has been prescribing brand-name weight-loss shots since January 2023, now offers compounded semaglutide to patients enrolled in its weight-management program. Nonetheless, Ro is the first prominent healthcare company to effectively endorse compounded semaglutide by prescribing it. A poor-quality compounded drug might simply be a dud and a waste of money. But while compounding pharmacies are subject to FDA and state regulations, states are the main regulators, and their oversight is patchy. Michael Siluk/UCG/Universal Images Group via Getty ImagesIt's hard to know if any given vial of compounded semaglutide is safe.
Persons: Wegovy's, Ro, drugmakers, Eli Lilly's, Eli Lilly's Mounjaro, Scott Gottlieb, Michael Siluk, That's, they've, Ozempic, Eli Lilly, Eric Kastango, they're, Kastango, aren't, Al Carter, Sarah Jones Simmer, Spencer Nadolsky, WeightWatchers, Tim Church, Wondr, it's, hasn't Organizations: Business, Novo Nordisk's Wegovy, US Food and Drug Administration, FDA, Novo Nordisk's Ozempic, Getty, Novo Nordisk, USP, National Association of, Pharmacy, Health Locations: Novo, Massachusetts, Austria, New York City
Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial. The condition is characterized by excess fat build-up and inflammation in the liver and can lead to liver scarring, also known as fibrosis. The trial followed around 190 adults with MASH with severe stages of liver scarring, Eli Lilly executives said on an earnings call Tuesday. It was less clear how much the drug reduced liver scarring, which was the second aim of the trial. Eli Lilly is "equally encouraged" by tirzepatide's results in reducing liver scarring, the company's chief scientific officer Dan Skovronsky said on the call.
Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Dan Skovronsky, David Risinger, Eli Lilly's Organizations: Leerink, Novo Nordisk Locations: New York City, U.S
The participants had their blood pressure monitored for a day before beginning treatment and again after nine months of weekly tirzepatide injections. The results showed a significant decrease in the participants’ systolic blood pressure, the top number in blood pressure readings, which is a strong predictor of heart disease. It works similarly to semaglutide, the active compound in the weight loss drug Wegovy and its sister diabetes drug, Ozempic. Although there are effective blood pressure medications available, only about a quarter of people with hypertension have adequately controlled blood pressure, Hall said. He views the weight loss effect of the drug as a pleasant side effect that will make people more likely to take their medication.
Persons: , Eli Lilly, , Harlan Krumholz, Michael E, Wegovy, it’s, Ania Jastreboff, Hall, Krumholz, tirzepatide, Dr, Sanjay Gupta, CNN’s Meg Tirrell Organizations: CNN, American Heart Association, Food and Drug Administration, Yale University, Department of Medicine, University of Mississippi Medical Center, Yale Obesity Research Center, CNN Health Locations: United States
Editor’s note: Season 9 of the podcast Chasing Life With Dr. Sanjay Gupta explores the intersection between body weight and health. But anyone who has ever dieted can tell you that losing weight is hard and that long-term weight loss requires sustained effort, which can sometimes feel Herculean, even impossible. If you are considering starting one of these medications, Moreno recommends keeping these five facts in mind. “On average, with semaglutide, the weight loss average can be close to 15%. This is the time to start changing some eating patterns that will be beneficial for weight loss.
Persons: Sanjay Gupta, Ozempic, It’s, Jorge Moreno, Moreno, ‘ You’ve, , ” Moreno, , Tirzepatide, Food and Drug Administration — “, They’re, ” They’re, , “ It’s, GERD, ” It’s, ’ ” Moreno Organizations: CNN, Yale School of Medicine, LinkedIn, Food and Drug Administration
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. Norway's giant wealth fund, the world's largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli Lilly could be on course to become the first healthcare members of the trillion-dollar club. Novo Nordisk, Europe's largest firm by market capitalization, on Wednesday reported stronger-than-anticipated 2023 earnings, as sales of its hugely popular drug Wegovy continued to soar. The largest pharmaceutical company in the world by market value, Eli Lilly currently stands at roughly $612 billion. NBIM, the world's biggest single stock market investor, holds a 2.5% stake in Novo Nordisk and a 0.98% stake in Eli Lilly, according to LSEG data.
Persons: Eli Lilly, Wegovy, Gemma Game, Eli Lilly's Zepbound Organizations: Novo Nordisk, Pharmacy, Norges Bank Investment Management, Nordisk's Ozempic Locations: Provo , Utah, U.S, Danish, Europe's
"Botched" star and plastic surgeon Terry Dubrow told Page Six that he tried Ozempic. Dubrow called the weight-loss drug "a miracle" but admitted it took "all the joy of eating away." He said he wanted to see what it's like if you're not diabetic and "only have 10-15 pounds to lose." Advertisement"Botched" star Terry Dubrow says he tried Ozempic but gave it up because it took "all the joy of eating away." In a Page Six interview alongside costar Paul Nassif, the plastic surgeon admitted to giving the weight-loss drug a go because he was curious about its effects.
Persons: Terry Dubrow, Dubrow, , Paul Nassif, Evan Real, Heather Dubrow — Organizations: Service, Page, Housewives, FDA Locations: Orange
Total: 25